Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$115.10

-2.51 (-2.13%)

, ZYNE

Zynerba

$6.67

-8.39 (-55.71%)

08:00
08/08/17
08/08
08:00
08/08/17
08:00

GW Pharmaceuticals downgraded to Hold from Buy at Maxim

Maxim analyst Gabrielle Zhou downgraded GW Pharmaceuticals (GWPH) to Hold after rival Zynerba Pharmaceuticals (ZYNE) reported a failed Phase 2 study evaluating a cannabidiol gel in adult epilepsy patients with focal seizures. The selloff yesterday in GW shares suggests investor concern that GW's botanically derived cannabidiol gel's benefit may be "moderate at best," Zhou tells investors in a research note. The analyst now sees a "more neutral" risk/reward for shares of GW.

GWPH

GW Pharmaceuticals

$115.10

-2.51 (-2.13%)

ZYNE

Zynerba

$6.67

-8.39 (-55.71%)

GWPH GW Pharmaceuticals
$115.10

-2.51 (-2.13%)

04/21/17
MAXM
04/21/17
INITIATION
Target $135
MAXM
Buy
GW Pharmaceuticals initiated with a Buy at Maxim
Maxim analyst Lauren Chung initiated GW Pharmaceuticals with a Buy rating and $135 price target, calling the company the "market leader" in cannabis therapeutics with a first-mover advantage in epilepsy.
05/25/17
LEER
05/25/17
NO CHANGE
LEER
Outperform
NEJM validation for Epidiolex, but controversy remains, says Leerink
Leerink analyst Paul Matteis believes publication of the first Dravet study in the New England Journal of Medicine offers "further validation of the robustness" of the positive phase III trial for GW Pharmaceuticals' Epidiolex. No new safety issues were disclosed and statistical sensitivity analyses corroborated the positive primary efficacy analysis, Matteis tells investors in a research note. Not included in the publication, however, is further color on the clobazam drug-drug interaction, which continues to remain a subject of investor controversy and interest heading into the mid-2017 new drug application filing, Matteis writes. He reiterates an Outperform rating on GW shares.
06/09/17
MAXM
06/09/17
NO CHANGE
MAXM
Buy
GW Pharmaceuticals orphan designation an incremental positive, says Maxim
Maxim analyst Gabrielle Zhou noted that GW Pharmaceuticals received FDA orphan designation for cannabidivarin for treatment of Fragile X syndrome, calling the news an incremental positive. The analyst, who notes that the next investor focus is the phase 2 data expected to be announced mid-2017 for GWP42006 in adult epilepsy, keeps a Buy rating on GW shares.
06/12/17
MAXM
06/12/17
NO CHANGE
Target $32
MAXM
Buy
Zynerba an 'excellent value' compared to GW Pharmaceuticals, says Maxim
Maxim analyst Gabrielle Zhou said she views Zynerba's (ZYNE) product candidates as "de-risked" alternatives to GW Pharmaceuticals' (GWPH) and calls the stock an "excellent value play" compared to GW, citing the facts that ZYN002 has a better safety and bioavailability profile than GW Pharma's Epidiolex. ZYN002 is also synthetic, not plant based, which could lead to higher margins and better quality control, Zhou tells investors. She keeps a Buy rating and $32 price target on Zynerba shares, adding that 2017 could be "transformational" for the company.
ZYNE Zynerba
$6.67

-8.39 (-55.71%)

08/07/17
CANT
08/07/17
DOWNGRADE
Target $4
CANT
Neutral
Zynerba downgraded to Neutral from Overweight at Cantor
Cantor Fitzgerald analyst Elemer Piros downgraded Zynerba Pharmaceuticals to Neutral and cut his price target for the shares to $4 from $28 following today's Phase 2 study failure. Piper Jaffray earlier also downgraded the shares.
08/07/17
MAXM
08/07/17
DOWNGRADE
MAXM
Hold
Zynerba downgraded to Hold from Buy at Maxim
08/07/17
MAXM
08/07/17
DOWNGRADE
MAXM
Hold
Zynerba downgraded to Hold after trial failure at Maxim
Maxim analyst Gabrielle Zhou downgraded Zynerba Pharmaceuticals to Hold from Buy saying she's uncertain about the clinical pathway forward for the company after ZYN002 failed a Phase 2 study in adult epilepsy with focal seizures. The analyst removed her price target for the shares. Piper Jaffray and Cantor Fitzgerald also downgraded Zynerba today.
08/08/17
HCWC
08/08/17
DOWNGRADE
Target $7
HCWC
Neutral
Zynerba downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis downgraded Zynerba Pharmaceuticals to Neutral and cut his price target for the shares to $7 from $30. The direction is unclear for ZYN002 in epilepsy after yesterday's Phase 2 failure, the analyst says. Davis removed all revenues for ZYN002 in epilepsy from his model.

TODAY'S FREE FLY STORIES

FLXN

Flexion

$27.40

0.63 (2.35%)

, ANIK

Anika Therapeutics

$45.99

0.9 (2.00%)

19:21
06/19/18
06/19
19:21
06/19/18
19:21
Recommendations
Flexion, Anika Therapeutics analyst commentary  »

Flexion to benefit from…

FLXN

Flexion

$27.40

0.63 (2.35%)

ANIK

Anika Therapeutics

$45.99

0.9 (2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ENSG

Ensign Group

$38.55

0.06 (0.16%)

19:07
06/19/18
06/19
19:07
06/19/18
19:07
Hot Stocks
Ensign Group subsidiary acquires office building in San Juan Capistrano »

The Ensign Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNOV

MediciNova

$8.37

-0.03 (-0.36%)

19:01
06/19/18
06/19
19:01
06/19/18
19:01
Hot Stocks
MediciNova receives Notice of Allowance from JPO for new patent covering MN-001 »

MediciNova announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAESY

BAE Systems

$0.00

(0.00%)

19:00
06/19/18
06/19
19:00
06/19/18
19:00
Hot Stocks
USMC awards BAE Systems $198M amphibious combat vehicle contract »

The U.S. Marine Corps has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$228.20

-3.185 (-1.38%)

18:59
06/19/18
06/19
18:59
06/19/18
18:59
Periodicals
Goldman plans to invest $500M in women-run companies, Reuters says »

Goldman Sachs intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

NTIP

Network-1 Technologies

$3.00

(0.00%)

, SYNA

Synaptics

$48.81

-0.35 (-0.71%)

18:50
06/19/18
06/19
18:50
06/19/18
18:50
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Network-1…

NTIP

Network-1 Technologies

$3.00

(0.00%)

SYNA

Synaptics

$48.81

-0.35 (-0.71%)

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

PRTA

Prothena

$14.99

0.43 (2.95%)

LZB

La-Z-Boy

$33.25

0.1 (0.30%)

ORCL

Oracle

$46.29

-0.25 (-0.54%)

FDX

FedEx

$258.35

-5.295 (-2.01%)

ANIK

Anika Therapeutics

$45.99

0.9 (2.00%)

KIN

Kindred Biosciences

$10.00

-0.55 (-5.21%)

SBUX

Starbucks

$57.43

0.22 (0.38%)

GE

General Electric

$12.96

-0.24 (-1.82%)

VALE

Vale

$12.97

-0.21 (-1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 22

    Jun

  • 28

    Jun

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

  • 20

    Sep

  • 21

    Sep

  • 20

    Jun

SD

SandRidge Energy

$17.03

1.21 (7.65%)

, IEP

Icahn Enterprises

$72.11

-0.62 (-0.85%)

18:44
06/19/18
06/19
18:44
06/19/18
18:44
Hot Stocks
SandRidge Energy reaches pact with Icahn Capital on board composition »

SandRidge Energy (SD)…

SD

SandRidge Energy

$17.03

1.21 (7.65%)

IEP

Icahn Enterprises

$72.11

-0.62 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$106.20

-0.85 (-0.79%)

18:32
06/19/18
06/19
18:32
06/19/18
18:32
Hot Stocks
Disney names Jennifer lee Walt Disney Animation Studios CCO »

Disney announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$6.20

0.05 (0.81%)

18:32
06/19/18
06/19
18:32
06/19/18
18:32
Syndicate
Trillium Therapeutics announces 'at-the-market' issuance program »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.39

0.19 (0.59%)

, GOOG

Alphabet

$1,167.86

-5.77 (-0.49%)

18:17
06/19/18
06/19
18:17
06/19/18
18:17
Periodicals
AT&T in discussions to purchase AppNexus, Cheddar reports »

AT&T (T) is in talks…

T

AT&T

$32.39

0.19 (0.59%)

GOOG

Alphabet

$1,167.86

-5.77 (-0.49%)

GOOGL

Alphabet Class A

$1,178.29

-5.69 (-0.48%)

FB

Facebook

$197.46

-0.84 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 28

    Oct

AAL

American Airlines

$41.51

-0.93 (-2.19%)

18:14
06/19/18
06/19
18:14
06/19/18
18:14
Periodicals
Breaking Periodicals news story on American Airlines »

American Airlines offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ZN

Zion Oil & Gas

$3.13

(0.00%)

18:13
06/19/18
06/19
18:13
06/19/18
18:13
Hot Stocks
Zion Oil & Gas to start operations at Megiddo-Jezreel #1 as soon as June 21 »

Zion Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$57.43

0.22 (0.38%)

18:10
06/19/18
06/19
18:10
06/19/18
18:10
Hot Stocks
Starbucks says China third party delivery 'was not a good experience' »

Comments taken from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 22

    Jun

EQH

AXA Equitable

$20.94

-0.01 (-0.05%)

18:07
06/19/18
06/19
18:07
06/19/18
18:07
Hot Stocks
Breaking Hot Stocks news story on AXA Equitable »

AXA Equitable reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

EQH

AXA Equitable

$20.94

-0.01 (-0.05%)

18:06
06/19/18
06/19
18:06
06/19/18
18:06
Earnings
AXA Equitable reports Q1 non-GAAP EPS 83c, consensus 82c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

BAESY

BAE Systems

$0.00

(0.00%)

18:06
06/19/18
06/19
18:06
06/19/18
18:06
Periodicals
USMC awards BAE contract to deliver new amphibious vehicles, Reuters says »

The U.S. Marine Corp has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNI

ATN International

$55.30

0.57 (1.04%)

18:04
06/19/18
06/19
18:04
06/19/18
18:04
Hot Stocks
ATN International acquires Geoverse LLC, terms not disclosed »

Geoverse, LLC, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

, GE

General Electric

$12.96

-0.24 (-1.82%)

18:01
06/19/18
06/19
18:01
06/19/18
18:01
Hot Stocks
Walgreens Boots Alliance to replace General Electric in DJIA at open on 6/26 »

Walgreens Boots Alliance…

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

GE

General Electric

$12.96

-0.24 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

HPE

HP Enterprise

$15.90

-0.02 (-0.13%)

18:01
06/19/18
06/19
18:01
06/19/18
18:01
Hot Stocks
HP Enterprise to invest $4B in Intelligent Edge technologies »

Hewlett Packard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

SBUX

Starbucks

$57.43

0.22 (0.38%)

, NSRGY

Nestle

$0.00

(0.00%)

17:59
06/19/18
06/19
17:59
06/19/18
17:59
Hot Stocks
Starbucks slips after announcing more store closures, cutting Q3 SSS view »

Shares of Starbucks…

SBUX

Starbucks

$57.43

0.22 (0.38%)

NSRGY

Nestle

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 22

    Jun

BX

Blackstone

$32.72

-0.31 (-0.94%)

, GS

Goldman Sachs

$228.20

-3.185 (-1.38%)

17:56
06/19/18
06/19
17:56
06/19/18
17:56
Hot Stocks
Blackstone to acquire PSAV »

PSAV announced that it…

BX

Blackstone

$32.72

-0.31 (-0.94%)

GS

Goldman Sachs

$228.20

-3.185 (-1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

SBUX

Starbucks

$57.43

0.22 (0.38%)

17:42
06/19/18
06/19
17:42
06/19/18
17:42
Recommendations
Starbucks analyst commentary  »

Starbucks has no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 22

    Jun

ORCL

Oracle

$46.29

-0.25 (-0.54%)

17:36
06/19/18
06/19
17:36
06/19/18
17:36
Hot Stocks
Breaking Hot Stocks news story on Oracle »

Oracle reverses, now down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

ORCL

Oracle

$46.29

-0.25 (-0.54%)

17:32
06/19/18
06/19
17:32
06/19/18
17:32
Earnings
Oracle sees Q1 adjusted EPS 67c-69c in USD, consensus 72c »

Sees Q1 adjusted EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

, GE

General Electric

$12.96

-0.24 (-1.82%)

17:32
06/19/18
06/19
17:32
06/19/18
17:32
Hot Stocks
Walgreens Boots Alliance to replace General Electric in DJIA »

Walgreens Boots Alliance…

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

GE

General Electric

$12.96

-0.24 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.